Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in Net LoansChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Change in Account Payables (2018 - 2024)

Abvc Biopharma (ABVC) has disclosed Change in Account Payables for 10 consecutive years, with $92972.0 as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Change in Account Payables rose 118.65% year-over-year to $92972.0, compared with a TTM value of -$252400.0 through Sep 2024, down 989.67%, and an annual FY2022 reading of $242469.0, up 176.4% over the prior year.
  • Change in Account Payables was $92972.0 for Q3 2024 at Abvc Biopharma, up from $24326.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $375454.0 in Q1 2023 and bottomed at -$498538.0 in Q3 2023.
  • Average Change in Account Payables over 5 years is $15685.7, with a median of $19361.5 recorded in 2020.
  • The sharpest move saw Change in Account Payables surged 1187.95% in 2021, then plummeted 2129.8% in 2023.
  • Year by year, Change in Account Payables stood at $267712.0 in 2020, then plummeted by 285.25% to -$495928.0 in 2021, then surged by 137.12% to $184067.0 in 2022, then crashed by 370.85% to -$498538.0 in 2023, then surged by 118.65% to $92972.0 in 2024.
  • Business Quant data shows Change in Account Payables for ABVC at $92972.0 in Q3 2024, $24326.0 in Q2 2024, and $128840.0 in Q1 2024.